603 related articles for article (PubMed ID: 22078153)
1. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
[TBL] [Abstract][Full Text] [Related]
2. A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials.
Cryer BL; Sostek MB; Fort JG; Svensson O; Hwang C; Hochberg MC
Ann Med; 2011 Dec; 43(8):594-605. PubMed ID: 22017620
[TBL] [Abstract][Full Text] [Related]
3. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences.
Anzellotti P; Capone ML; Jeyam A; Tacconelli S; Bruno A; Tontodonati P; Di Francesco L; Grossi L; Renda G; Merciaro G; Di Gregorio P; Price TS; Garcia Rodriguez LA; Patrignani P
Arthritis Rheum; 2011 Mar; 63(3):850-9. PubMed ID: 21360514
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers.
Sostek MB; Fort JG; Estborn L; Vikman K
Curr Med Res Opin; 2011 Apr; 27(4):847-54. PubMed ID: 21319944
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium.
Wang-Smith L; Fort J; Zhang Y; Sostek M
J Clin Pharmacol; 2012 May; 52(5):670-80. PubMed ID: 21628602
[TBL] [Abstract][Full Text] [Related]
6. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin.
Schiff M; Hochberg MC; Oldenhof J; Brune K
Curr Med Res Opin; 2009 Oct; 25(10):2471-7. PubMed ID: 19678751
[TBL] [Abstract][Full Text] [Related]
7. Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies.
Angiolillo DJ; Datto C; Raines S; Yeomans ND
J Thromb Thrombolysis; 2014 Jul; 38(1):11-23. PubMed ID: 24368727
[TBL] [Abstract][Full Text] [Related]
8. Effect of maximum OTC doses of naproxen sodium or acetaminophen on low-dose aspirin inhibition of serum thromboxane B2.
Oldenhof J; Hochberg M; Schiff M; Brune K
Curr Med Res Opin; 2010 Jun; 26(6):1497-504. PubMed ID: 20429831
[TBL] [Abstract][Full Text] [Related]
9. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Goldstein JL; Cryer B; Amer F; Hunt B
Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, Phase I study in healthy volunteers.
Miner P; Plachetka J; Orlemans E; Fort JG; Sostek M
Aliment Pharmacol Ther; 2010 Aug; 32(3):414-24. PubMed ID: 20491746
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers.
Cryer B; Berlin RG; Cooper SA; Hsu C; Wason S
Clin Ther; 2005 Feb; 27(2):185-91. PubMed ID: 15811481
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects.
Capone ML; Sciulli MG; Tacconelli S; Grana M; Ricciotti E; Renda G; Di Gregorio P; Merciaro G; Patrignani P
J Am Coll Cardiol; 2005 Apr; 45(8):1295-301. PubMed ID: 15837265
[TBL] [Abstract][Full Text] [Related]
14. Naproxen/esomeprazole (Vimovo).
Med Lett Drugs Ther; 2010 Sep; 52(1347):74-5. PubMed ID: 20847717
[No Abstract] [Full Text] [Related]
15. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
Daniels S; Robbins J; West CR; Nemeth MA
Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
Choi Y; Han H; Shin D; Lim KS; Yu KS
Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
[TBL] [Abstract][Full Text] [Related]
18. Human pharmacology of naproxen sodium.
Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
[TBL] [Abstract][Full Text] [Related]
19. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women.
Ridker PM; Hennekens CH; Tofler GH; Lipinska I; Buring JE
J Cardiovasc Risk; 1996 Apr; 3(2):209-12. PubMed ID: 8836865
[TBL] [Abstract][Full Text] [Related]
20. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor.
Goldstein JL; Lowry SC; Lanza FL; Schwartz HI; Dodge WE
Aliment Pharmacol Ther; 2006 May; 23(10):1489-98. PubMed ID: 16669964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
